

Date: 25.01.2019

To

Nilesh S Jain Assistant Manager Surveillance, BSE Limited, P J Towers, Dalal Street, Mumbai – 400 001 BSE - Code: 532660

Mayur Jain,
Deputy Manager - Surveillance
National Stock Exchange of India
Limited(NSE), Exchange Plaza, Bandra
Kurla Complex, Bandra East, Mumbai 400051

NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam.

Sub.: Clarification on Price Movement - reg.

This is with reference to BSE email/Letter no. L/SURV/ONL/PV/PA/ 2018-2019 / 225 dated 23.1.2019 & NSE email/Letter no. NSE/CM/Surveillance/7855 dated 23.1.2019 relating to the Price Movement of our scrip in the exchanges. In this regard, we would like to bring to your kind attention that the Company has made all the necessary disclosures in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 from time to time and has not withheld any material information/event that in our opinion would have a bearing on the price/volume behaviour in our scrip. The same has been communicated by us in our earlier letter to the exchanges on 21.1.2019.

The spurt in volume of our scrip and impact of share price is purely market driven.

However 18,00,000 equity shares pledged by promoters has been invoked by the lenders on 22.01.2019.

Kindly take the above on your records.

Kindly acknowledge the receipt of the same.

Thanking you Yours Truly,

For Vivimed Labs Limited

Santosh Varalwar Managing Director

